CD30 阳性淋巴增殖性疾病

CD30-Positive Lymphoproliferative Disorders.

作者信息

Nikolaenko Liana, Zain Jasmine, Rosen Steven T, Querfeld Christiane

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

Toni Stephenson Lymphoma Center, City of Hope National Medical Center, Duarte, CA, USA.

出版信息

Cancer Treat Res. 2019;176:249-268. doi: 10.1007/978-3-319-99716-2_12.

DOI:10.1007/978-3-319-99716-2_12

PMID:30596222

Abstract

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Both LyP and pcALCL show numerous clinical, histological and immunophenotypic variants, and generally have an indolent course with a favorable prognosis. Overlapping features of LyP and pcALCL with other CD30+ T-cell lymphomas, inflammatory, and/or infectious conditions emphasize the importance of careful clinicopathologic correlation and staging.

摘要

原发性皮肤CD30阳性淋巴增殖性疾病（CD30+ LPD）包括淋巴瘤样丘疹病（LyP）、原发性皮肤间变性大细胞淋巴瘤（pcALCL）和交界性病变[1]。CD30+ LPD是仅次于蕈样肉芽肿（MF）的第二常见皮肤T细胞淋巴瘤（CTCL），约占所有CTCL病例的25%[2]。它们共同的表型特征是CD30抗原的表达，CD30抗原是一种属于肿瘤坏死因子（TNF）受体超家族的细胞因子受体。LyP和pcALCL均表现出众多临床、组织学和免疫表型变异，且通常病程惰性，预后良好。LyP和pcALCL与其他CD30+ T细胞淋巴瘤、炎症和/或感染性疾病的重叠特征强调了仔细进行临床病理相关性分析和分期的重要性。